Sino Biopharmaceutical Limited (01177.HK) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	33.7B	31.8B	28.9B	26.2B	26.0B
Cost of Revenue	5.9B	5.7B	5.3B	5.0B	5.8B
Gross Profit	27.8B	26.1B	23.5B	21.2B	21.5B
Operating Expenses
R&D Expense	5.9B	6.0B	5.2B	4.5B	4.3B
SG&A Expense	11.8B	13.1B	12.2B	11.1B	12.6B
General & Admin Expense	2.0B	2.1B	2.1B	1.9B	2.2B
Selling & Marketing Expense	9.8B	11.0B	10.1B	9.2B	9.8B
Other Expenses	—	—	—	—	(943.9M)
Total Operating Expenses	17.8B	19.2B	17.4B	15.5B	16.0B
Cost and Expenses	23.7B	24.9B	22.7B	20.5B	20.4B
Operating Income (EBIT)	10.0B	7.0B	6.1B	5.8B	5.6B
Non-Operating
Interest Income	—	617.2M	499.6M	186.7M	195.9M
Interest Expense	—	271.1M	295.1M	495.2M	429.5M
Net Interest Income	568.2M	346.1M	204.4M	(308.6M)	(233.6M)
Other Non-Op Income/Expense	(1.7B)	(10.2M)	(858.1M)	(375.8M)	(371.0M)
Non-Operating Income (excl Interest)	534.5M	662.3M	1.1B	(119.4M)	200.0M
EBT (Pre-Tax Income)	8.3B	6.9B	5.3B	5.4B	5.2B
Income Tax Expense	1.8B	1.6B	492.9M	797.3M	696.7M
Bottom Line
Net Income	2.4B	2.3B	3.5B	2.3B	2.5B
Earnings from Cont. Ops	6.5B	5.3B	4.8B	4.6B	4.5B
Earnings from Discont. Ops	—	—	1.6B	484.8M	484.5M
Bottom Line Net Income	2.4B	2.3B	1.9B	1.8B	2.1B
Per Share
Basic EPS	HK$0.13	HK$0.13	HK$0.20	HK$0.10	HK$0.11
Diluted EPS	HK$0.13	HK$0.13	HK$0.19	HK$0.10	HK$0.12
Revenue Per Share	HK$1.87	HK$1.76	HK$1.67	HK$1.41	HK$1.40
Shares
Basic Shares Outstanding	18.0B	18.1B	17.2B	18.5B	18.6B
Diluted Shares Outstanding	18.0B	18.1B	18.3B	18.5B	19.0B
Profitability Metrics
EBITDA	10.4B	7.3B	6.1B	7.0B	6.7B
D&A	915.9M	963.9M	939.9M	1.1B	1.0B
EBIT	9.5B	6.3B	5.2B	5.9B	5.6B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026